KR102720992B1 - 피롤리딘 화합물 - Google Patents

피롤리딘 화합물 Download PDF

Info

Publication number
KR102720992B1
KR102720992B1 KR1020247002433A KR20247002433A KR102720992B1 KR 102720992 B1 KR102720992 B1 KR 102720992B1 KR 1020247002433 A KR1020247002433 A KR 1020247002433A KR 20247002433 A KR20247002433 A KR 20247002433A KR 102720992 B1 KR102720992 B1 KR 102720992B1
Authority
KR
South Korea
Prior art keywords
tert
oxo
methyl
mmol
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020247002433A
Other languages
English (en)
Korean (ko)
Other versions
KR20240014618A (ko
Inventor
셀리아 라푸엔테 블랑코
누리아 디아즈 부에조
호세 안토니오 마르티네즈 페레즈
헤마 콘수엘로 산스 힐
훌리안 프리에고 솔레르
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20240014618A publication Critical patent/KR20240014618A/ko
Application granted granted Critical
Publication of KR102720992B1 publication Critical patent/KR102720992B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1020247002433A 2019-06-07 2020-06-03 피롤리딘 화합물 Active KR102720992B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19382477.8 2019-06-07
EP19382477 2019-06-07
KR1020227043106A KR102629923B1 (ko) 2019-06-07 2020-06-03 피롤리딘 화합물
PCT/US2020/035825 WO2020247429A1 (en) 2019-06-07 2020-06-03 Pyrrolidine compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227043106A Division KR102629923B1 (ko) 2019-06-07 2020-06-03 피롤리딘 화합물

Publications (2)

Publication Number Publication Date
KR20240014618A KR20240014618A (ko) 2024-02-01
KR102720992B1 true KR102720992B1 (ko) 2024-10-24

Family

ID=66821161

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247002433A Active KR102720992B1 (ko) 2019-06-07 2020-06-03 피롤리딘 화합물
KR1020227043106A Active KR102629923B1 (ko) 2019-06-07 2020-06-03 피롤리딘 화합물
KR1020217040065A Active KR102477481B1 (ko) 2019-06-07 2020-06-03 피롤리딘 화합물

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020227043106A Active KR102629923B1 (ko) 2019-06-07 2020-06-03 피롤리딘 화합물
KR1020217040065A Active KR102477481B1 (ko) 2019-06-07 2020-06-03 피롤리딘 화합물

Country Status (25)

Country Link
US (3) US11286249B2 (enExample)
EP (1) EP3980409A1 (enExample)
JP (5) JP6940717B2 (enExample)
KR (3) KR102720992B1 (enExample)
CN (1) CN114008021B (enExample)
AU (1) AU2020287599B2 (enExample)
BR (1) BR112021023347A2 (enExample)
CL (1) CL2021003202A1 (enExample)
CO (1) CO2021016295A2 (enExample)
CR (1) CR20210602A (enExample)
DO (1) DOP2021000254A (enExample)
EA (1) EA202193007A1 (enExample)
EC (1) ECSP21088515A (enExample)
IL (2) IL288174B2 (enExample)
JO (1) JOP20210319B1 (enExample)
MA (1) MA56115A (enExample)
MX (2) MX2021014913A (enExample)
MY (1) MY200810A (enExample)
PE (1) PE20220134A1 (enExample)
PH (1) PH12021553062A1 (enExample)
SA (1) SA521431048B1 (enExample)
SG (1) SG11202113244UA (enExample)
UA (1) UA128540C2 (enExample)
WO (1) WO2020247429A1 (enExample)
ZA (1) ZA202109251B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023078333A1 (zh) 2021-11-03 2023-05-11 上海拓界生物医药科技有限公司 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途
EP4469435A1 (en) * 2022-01-26 2024-12-04 Eli Lilly and Company Pyrrolidine compounds
US20260234125A1 (en) * 2023-03-24 2026-08-13 Shanghai Jingxin Biomedical Co., Ltd. Cyclic amine derivative, and composition and use thereof
WO2024217537A1 (zh) * 2023-04-21 2024-10-24 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
TW202444710A (zh) 2023-05-11 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 一種脂蛋白化合物晶型及其製備方法
CN122167331A (zh) 2023-05-19 2026-06-09 深圳信立泰药业股份有限公司 一种磺酰胺类化合物及其制备方法和医药用途
IL324569A (en) 2023-06-30 2026-01-01 Lilly Co Eli Therapeutic uses and doses of lp(a) disrupter compounds
JP2026524960A (ja) 2023-07-21 2026-07-24 イーライ リリー アンド カンパニー Ｌｐ（ａ）低下活性を有するピペリジン化合物
KR20260041098A (ko) 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
CN121548567A (zh) 2023-07-21 2026-02-17 伊莱利利公司 具有Lp(a)降低活性的哌啶、吗啉和四氢哒嗪化合物
KR20260041097A (ko) 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
CN122535600A (zh) * 2023-11-17 2026-08-07 上海翊石医药科技有限公司 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途
CN122270439A (zh) * 2023-11-20 2026-06-23 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
WO2025255324A1 (en) * 2024-06-06 2025-12-11 Lapis Therapeutics, Inc. Inhibitors of lipoprotein(a) assembly
CN121627662A (zh) * 2024-09-05 2026-03-10 成都康弘药业集团股份有限公司 芳基丙酸化合物及其制备方法与用途
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
WO2026098459A1 (zh) * 2024-11-06 2026-05-15 上海翊石医药科技有限公司 一种取代的2-(吡咯烷-3-基)乙酸衍生物的晶型及其制备方法和用途
US20260130887A1 (en) * 2024-11-14 2026-05-14 Eli Lilly And Company Oral compositions comprising lp(a) inhibitor compounds
WO2026108936A1 (zh) * 2024-11-20 2026-05-28 深圳信立泰药业股份有限公司 一种化合物a可药用盐以及包含该化合物a可药用盐的药物组合物
WO2026108938A1 (zh) * 2024-11-20 2026-05-28 深圳信立泰药业股份有限公司 一种化合物a或其盐的无定型以及包含该无定形的药物组合物
WO2026119122A1 (zh) * 2024-12-02 2026-06-11 上海喆邺生物科技有限公司 一种苯丙酸衍生物及其医药用途
WO2026130543A1 (zh) * 2024-12-20 2026-06-25 上海维亚聃诚创业孵化器管理有限公司 多芳香环化合物、其组合物及用途
WO2026145708A1 (zh) * 2025-01-02 2026-07-09 上海喆邺生物科技有限公司 一种芳香酸类化合物及其医药用途
CN121135622A (zh) * 2025-04-11 2025-12-16 柴永帅 杂环化合物及其药物组合物和应用
CN121609698B (zh) * 2026-01-30 2026-06-02 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068412A1 (en) 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
WO2005068410A1 (en) 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2685325B1 (fr) * 1991-12-20 1994-02-04 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
KR101133862B1 (ko) 2007-07-27 2012-04-06 에프. 호프만-라 로슈 아게 Ｔａａｒ 리간드로서의 2-아제티딘메테인아민 및 2-피롤리딘메테인아민
JP2019505508A (ja) 2016-02-03 2019-02-28 シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． 複素環置換ｎ−スルホニルベンズアミド誘導体、その製造方法および医薬における使用
CN112321475B (zh) 2020-11-13 2022-06-10 四川大学 一种γ-氨基酸类似物及其合成方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005068412A1 (en) 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
WO2005068410A1 (en) 2003-12-24 2005-07-28 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses

Also Published As

Publication number Publication date
JP7508422B2 (ja) 2024-07-01
ECSP21088515A (es) 2022-01-31
JP2024123111A (ja) 2024-09-10
DOP2021000254A (es) 2022-01-16
US11286249B2 (en) 2022-03-29
IL321703A (en) 2025-08-01
EA202193007A1 (ru) 2022-03-25
US20260055086A1 (en) 2026-02-26
JP2026126294A (ja) 2026-08-04
EP3980409A1 (en) 2022-04-13
CN114008021B (zh) 2024-11-05
JP6940717B2 (ja) 2021-09-29
IL288174B1 (en) 2025-08-01
JP2021191784A (ja) 2021-12-16
US20220169636A1 (en) 2022-06-02
AU2020287599B2 (en) 2023-10-19
MY200810A (en) 2024-01-16
CO2021016295A2 (es) 2021-12-10
JOP20210319A1 (ar) 2023-01-30
IL321703B2 (en) 2026-08-01
JP7658014B2 (ja) 2025-04-07
NZ782992A (en) 2025-02-28
MA56115A (fr) 2022-04-13
US12441714B2 (en) 2025-10-14
SG11202113244UA (en) 2021-12-30
AU2020287599A1 (en) 2022-01-06
JP2025098178A (ja) 2025-07-01
CL2021003202A1 (es) 2022-09-09
IL288174B2 (en) 2025-12-01
KR20240014618A (ko) 2024-02-01
ZA202109251B (en) 2024-04-24
PH12021553062A1 (en) 2022-08-15
JP2021524498A (ja) 2021-09-13
IL288174A (en) 2022-01-01
KR20230004890A (ko) 2023-01-06
UA128540C2 (uk) 2024-08-07
US20210253559A1 (en) 2021-08-19
CN114008021A (zh) 2022-02-01
KR20220018494A (ko) 2022-02-15
KR102629923B1 (ko) 2024-01-30
WO2020247429A1 (en) 2020-12-10
PE20220134A1 (es) 2022-01-27
IL321703B1 (en) 2026-04-01
MX2025001789A (es) 2025-03-07
CA3140869A1 (en) 2020-12-10
JOP20210319B1 (ar) 2024-12-22
SA521431048B1 (ar) 2024-04-28
CR20210602A (es) 2022-01-06
BR112021023347A2 (pt) 2022-04-12
KR102477481B1 (ko) 2022-12-15
MX2021014913A (es) 2022-01-18

Similar Documents

Publication Publication Date Title
KR102629923B1 (ko) 피롤리딘 화합물
KR102841588B1 (ko) Pd-l1 질환의 치료를 위한 화합물
CN111225896B (zh) 免疫调节剂化合物
WO2012117421A1 (en) Histone deacetylase inhibitors
JP5355551B2 (ja) キノロン化合物及び医薬組成物
JP2020505440A (ja) Ｈｄａｃ６選択的阻害剤およびその製造方法と使用
JPWO2020138398A1 (ja) リジン特異的脱メチル化酵素１を阻害する新規化合物、その製造方法及びその用途
EP2280940A1 (en) Novel n-(2-amino-phenyl)-acrylamides
JP2012012388A (ja) 医薬
CA3140869C (en) Pyrrolidine compounds
EA045074B1 (ru) Соединения пирролидина
WO2025024211A1 (en) Piperidine Compounds with Lp(a) Lowering Activity
AU2024298539A1 (en) PYRROLIDINE COMPOUNDS WITH Lp(a) LOWERING ACTIVITY
KR20250117821A (ko) Hdac 억제제 및 이의 용도
CN121517394A (zh) 一种取代的吡啶丙酸衍生物及其用途
JP2009185010A (ja) グリシントランスポーター阻害剤を含有する医薬

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601